Antek Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
- Paid Up Capital ₹ 0.10 M
- Company Age 23 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -56.59%
- Ebitda -61.29%
- Net Worth 15.14%
- Total Assets 15.14%
About Antek Drugs
Antek Drugs Private Limited (ADPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 July 2001 and has a history of 23 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Mehta and Dinesh Kakar serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232DL2001PTC111537
- Company No.
111537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jul 2001
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Antek Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Mehta  | Director | 06-Apr-2015 | Current |
| Dinesh Kakar | Director | 24-Feb-2015 | Current |
Financial Performance of Antek Drugs.
Antek Drugs Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 56.59% decrease in profit. The company's net worth Soared by an impressive increase of 15.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Antek Drugs?
In 2022, Antek Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lanark Laboratories Pvt LtdAnil Mehta and Dinesh Kakar are mutual person
Deventure Hotels Private LimitedDinesh Kakar is a mutual person
Zee Laboratories LimitedAnil Mehta is a mutual person
Zeelab Pharmacy Private LimitedDinesh Kakar is a mutual person
Klokter Life Sciences Private LimitedDinesh Kakar is a mutual person
- Zee Biosciences Private Limited
Dinesh Kakar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Antek Drugs?
Unlock and access historical data on people associated with Antek Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Antek Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Antek Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
